Affiliation:
1. Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine
Abstract
Cancer patients are at increased risk of venous thromboembolic complications (VTE), which are the second leading cause of death in these patients. Moreover, the maximum incidence of VTE occurs in tumors of the central nervous system [1]. Research is being conducted to identify laboratory biomarkers of increased risk of VTE, but to date data on their role are ambiguous. Patients with a mutation in the isocitrate dehydrogenase (IDH) gene are at lower risk of VTE, and the IDH mutation is associated with suppression of the production of tissue factor (TF) and podoplanin, the most studied molecules responsible for the occurrence of thromboembolic complications [2]. The main specific markers of VTE are based on immunohistochemical methods, which are possible only with histological examination of the tumor material. Therefore, it is important to find noninvasive biomarkers that could be used to assess the risk of venous thromboembolic complications. In this review, we will focus on highlighting the accumulated knowledge on this theme.
Publisher
Arterialnaya Gipertenziya
Reference44 articles.
1. Khorana AA, et al. Cancer-associated venous thromboembolism //Nature Reviews Disease Primers. 2022. Vol. 8. No. 1. P. 11.
2. Jo J, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review //Neuro-oncology. 2023. P. noad059.
3. Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis // Thrombosis research. 2015. Vol. 135. P. S8–S11.
4. Somonova O.V. i dr. Prakticheskie rekomendatsii po profilaktike i lecheniyu tromboembolicheskikh oslozhnenii u onkologicheskikh bol'nykh // Zlokachestvennye opukholi. 2021. Vol. 11. No. 3S2–2. P. 145–155.
5. ESC Scientific Document Group et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) //European heart journal cardiovascular Imaging. 2022. Vol. 23. No. 10. P. E333–E465.